Fabrinet (NYSE:FN) represented a move of 1.95 percent or $-0.65 per share and closed its previous day trading session at $29.22. 521724 Shares were traded in the last trading session with an Average Volume of 646.06 Million Shares. The stock currently has a Market Capitalization of 1.08 Billion.
Fabrinet provides precision optical, electro-mechanical and electronic manufacturing services to original equipment manufacturers of complex products, such as optical communication components, modules and sub-systems, industrial lasers and sensors. The Company offers a broad range of advanced optical capabilities across the entire manufacturing process, including process engineering, design for manufacturability, supply chain management, manufacturing, final assembly and test. Fabrinet manufactures, assembles, and tests products for customers at its main manufacturing facilities in Bangkok, Thailand. The Company designs and manufactures its own bulk optical materials and components at its facilities in Fuzhou, the People’s Republic of China, and New Jersey, USA.
The stock traded between $24.02 and $49.63 over 1-Year time period showing its price to sales ratio of 0.75. Fabrinet (NYSE:FN) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a INCREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $2.18 and 200-Day Simple Moving Average of $-18.17. Its Price to Free Cash Flow is 0 and Price to Book of 1.52.
Analyst’s recommended the stock as 1.6 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, Fabrinet (NYSE:FN) reported its Actual EPS of $0.72/share. The analysts offering Earnings Estimates for the company were believing that Fabrinet could bring EPS of $0.7/share. The difference between Actual EPS and Estimated EPS was 0.02 Percent. Thus showing an Earnings Surprise of 2.9 Percent.
Radius Health, Inc. (NASDAQ:RDUS)
In the last trading session, Radius Health, Inc. (NASDAQ:RDUS) added its value by 2.11% closing at the price of $38.63. The stock currently has market capitalization of 1.64 Billion, with average volume of 895.38 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Radius Health, Inc. (NASDAQ:RDUS) is showing beta of 1.31. This particular value of beta suggests that Radius Health, Inc. (NASDAQ:RDUS) has historically moved 131% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Radius Health, Inc. (NASDAQ:RDUS) is at $-5.43.
The stock currently has RSI of 59.93. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Radius Health Inc. is a science-driven biopharmaceutical company. It is focused on developing novel differentiated therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases. The Company’s lead product candidate, abaloparatide (BA058), is in development, in both injection (Abaloparatide-SC) and transdermal (Abaloparatide-TD) methods of administration, for the prevention of fractures in post-menopausal women at risk of fracture from osteoporosis. Radius Health Inc. is based in Cambridge, Massachusetts.
Radius Health, Inc. (NASDAQ:RDUS) topped its 52-week high price of $49.16 on 07/12/17 and 52-Week Low Price of $24.66 on 11/14/17. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 7.28% and monthly volatility of 5.66% respectively.